Profile data is unavailable for this security.
About the company
Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
- Revenue in USD (TTM)102.43m
- Net income in USD-28.05m
- Incorporated1996
- Employees163.00
- LocationRigel Pharmaceuticals Inc1180 Veterans BlvdSOUTH SAN FRANCISCO 94080-1985United StatesUSA
- Phone+1 (650) 624-1100
- Fax+1 (650) 624-1101
- Websitehttps://www.rigel.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spero Therapeutics Inc | 12.13m | -79.11m | 282.36m | 57.00 | -- | 3.38 | -- | 23.28 | -4.19 | -4.19 | 0.6474 | 4.05 | 0.1034 | -- | 8.95 | 212,807.00 | -67.46 | -- | -77.25 | -- | -- | -- | -652.19 | -- | -- | -- | 0.00 | -- | 357.56 | -- | -46.24 | -- | -- | -- |
| Pfenex Inc | 40.65m | -5.43m | 283.25m | 85.00 | -- | 3.40 | -- | 6.97 | -0.1878 | -0.1878 | 1.23 | 2.43 | 0.4929 | -- | 7.97 | 501,802.50 | -6.59 | -18.37 | -7.39 | -21.99 | 89.94 | 83.19 | -13.36 | -53.10 | -- | -- | 0.00 | -- | 238.74 | 36.44 | 102.67 | -- | 35.47 | -- |
| Bicycle Therapeutics PLC (ADR) | 8.55m | -35.43m | 284.25m | 72.00 | -- | 3.46 | -- | 33.26 | -1.97 | -1.97 | 0.4763 | 4.54 | 0.0825 | -- | 13.54 | 118,694.40 | -34.22 | -- | -38.83 | -- | -- | -- | -414.57 | -- | -- | -- | 0.00 | -- | 93.40 | -- | -40.11 | -- | -- | -- |
| Abeona Therapeutics Inc | 0.00 | -105.89m | 284.57m | 88.00 | -- | 2.15 | -- | -- | -1.66 | -1.66 | 0.00 | 1.58 | 0.00 | -- | -- | 0.00 | -62.08 | -29.61 | -74.80 | -32.36 | -- | -- | -- | -3,412.06 | -- | -- | 0.00 | -- | -100.00 | -- | -34.61 | -- | -- | -- |
| Sutro Biopharma Inc | 41.26m | -61.09m | 287.51m | 177.00 | -- | 2.38 | -- | 6.97 | -2.65 | -2.65 | 1.79 | 3.53 | 0.2316 | -- | 6.65 | 245,589.30 | -34.29 | -- | -41.67 | -- | -- | -- | -148.06 | -- | -- | -85.41 | 0.2274 | -- | 11.24 | -- | -57.84 | -- | -- | -- |
| Menlo Therapeutics Inc | 1.75m | -95.06m | 289.99m | 180.00 | -- | 1.53 | -- | 165.71 | -3.23 | -3.23 | 0.0611 | 1.13 | 0.0122 | -- | -- | 43,750.00 | -66.29 | -- | -86.59 | -- | 84.51 | -- | -5,432.17 | -- | 1.68 | -- | 0.3206 | -- | -100.00 | -- | -43.27 | -- | -- | -- |
| Concert Pharmaceuticals Inc | 79.00k | -76.82m | 296.24m | 70.00 | -- | 1.92 | -- | 3,749.83 | -3.07 | -3.07 | 0.0031 | 5.21 | 0.0004 | -- | 13.17 | 1,128.57 | -41.45 | -8.54 | -44.09 | -9.08 | -- | -- | -97,236.71 | -29.27 | -- | -- | 0.00 | -- | -89.75 | -33.96 | -39.52 | -- | -3.15 | -- |
| Liquidia Technologies Inc | 8.07m | -48.61m | 297.04m | 64.00 | -- | 10.25 | -- | 36.80 | -2.26 | -2.26 | 0.3742 | 0.7675 | 0.1276 | -- | -- | 126,126.90 | -76.85 | -- | -97.77 | -- | 90.00 | -- | -602.17 | -- | -- | -57.97 | 0.4309 | -- | 198.20 | -- | 10.45 | -- | -- | -- |
| Urovant Sciences Ltd | 0.00 | -146.75m | 310.15m | 70.00 | -- | -- | -- | -- | -4.82 | -4.82 | 0.00 | -1.89 | 0.00 | -- | -- | 0.00 | -179.60 | -- | -243.22 | -- | -- | -- | -- | -- | -- | -38.74 | 2.59 | -- | -- | -- | -31.79 | -- | -- | -- |
| Cellular Biomedicine Group Inc | 290.66k | -52.19m | 318.41m | 217.00 | -- | 7.04 | -- | 1,095.46 | -2.71 | -2.71 | 0.0151 | 2.33 | 0.0028 | -- | 1.12 | 1,339.45 | -50.37 | -49.83 | -61.77 | -54.56 | 81.32 | 23.14 | -17,957.33 | -4,413.84 | -- | -- | 0.2367 | -- | 51.48 | -9.64 | -28.34 | -- | 104.77 | -- |
| Rigel Pharmaceuticals, Inc. | 102.43m | -28.05m | 320.28m | 163.00 | -- | 4.08 | -- | 3.13 | -0.1684 | -0.1684 | 0.6106 | 0.4657 | 0.648 | 0.6933 | 13.41 | 628,374.30 | -17.75 | -54.29 | -21.68 | -69.95 | 99.07 | -- | -27.39 | -213.28 | 3.68 | -- | 0.1113 | -- | 33.20 | 48.36 | 5.09 | -- | 28.64 | -- |
| PDL BioPharma Inc | 54.06m | -93.50m | 334.50m | 75.00 | -- | 0.6223 | -- | 6.19 | -0.7845 | -0.9035 | 0.4573 | 4.62 | 0.0683 | 4.04 | 3.20 | 720,746.70 | -11.87 | 6.98 | -12.55 | 7.77 | 2.55 | -- | -173.90 | 26.17 | 12.95 | -- | 0.0235 | 31.21 | -72.36 | -37.65 | -2.25 | -- | -50.29 | -- |
| Aspira Women's Health Inc | 4.96m | -15.23m | 343.26m | 52.00 | -- | 64.68 | -- | 69.27 | -0.1688 | -0.1688 | 0.0539 | 0.0545 | 0.5326 | 42.84 | 6.02 | 95,288.46 | -163.67 | -106.43 | -269.84 | -139.72 | 30.39 | 7.24 | -307.31 | -458.36 | 2.49 | -- | 0.19 | -- | 48.64 | 12.48 | -34.00 | -- | -12.41 | -- |
| Wave Life Sciences Ltd | 17.12m | -196.93m | 344.46m | 301.00 | -- | 15.99 | -- | 20.12 | -5.74 | -5.74 | 0.4987 | 0.8304 | 0.0512 | -- | 3.42 | 56,870.43 | -58.86 | -54.34 | -94.13 | -71.05 | -- | -- | -1,150.43 | -1,455.31 | -- | -- | 0.00 | -- | 10.89 | -- | -32.04 | -- | 46.03 | -- |
| Emisphere Technologies, Inc. | 1.04m | -2.15m | 349.29m | 12.00 | -- | -- | -- | 334.57 | -0.0476 | -0.0476 | 0.0166 | -2.55 | 0.1162 | 2.18 | 3.90 | -- | -23.92 | -287.20 | -- | -- | -43.20 | -48.94 | -205.75 | -6,143.77 | 0.7765 | -- | -- | -- | 190.75 | -- | 75.13 | -- | -- | -- |
Data as of Jul 07 2020. Currency figures normalised to Rigel Pharmaceuticals Inc's reporting currency: US Dollar USD
54.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2020 | 22.05m | 13.08% |
| Wellington Management Co. LLPas of 31 Mar 2020 | 15.71m | 9.32% |
| BlackRock Fund Advisorsas of 31 Mar 2020 | 13.06m | 7.75% |
| The Vanguard Group, Inc.as of 31 Mar 2020 | 8.35m | 4.96% |
| Millennium Management LLCas of 31 Mar 2020 | 8.16m | 4.84% |
| Tamarack Advisers LPas of 31 Mar 2020 | 5.55m | 3.29% |
| Rock Springs Capital Management LPas of 31 Mar 2020 | 5.50m | 3.26% |
| Invesco Advisers, Inc.as of 31 Mar 2020 | 5.00m | 2.97% |
| Renaissance Technologies LLCas of 31 Mar 2020 | 4.21m | 2.50% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2020 | 3.94m | 2.34% |
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
